Sensei is a biopharmaceutical company engaged in to the discovery, development and delivery of next-generation immunotherapies for the treatment of cancer. The company is developing a pipeline of medicines designed to fulfill the substantial potential of the immune system to defeat cancer and other diseases. It has developed two unique approaches. The first approach is Sensei’s proprietary ImmunoPhage™ platform, which leverages the self-adjuvanted and highly immunogenic properties of engineered bacteriophage. This platform allows Sensei to develop novel therapeutics that target key mechanisms of checkpoint resistance to induce a robust, focused and coordinated immune response. The second approach is the company’s monoclonal antibody and nanobody platform, which is comprised of unique human monoclonal antibodies and alpaca-derived nanobodies that are selectively active only in the tumor microenvironment.
Sensei is developing a library of ImmunoPhage targeting multiple tumor-associated antigens, also known as PhortressTM, utilizing its proprietary platform and GMP manufacturing facility to treat patients using a personalized, yet off the shelf cocktail approach.
Sensei’s ImmunoPhage programs include SNS-401-NG, a preclinical candidate for the treatment of Merkel cell carcinoma and a human monoclonal antibody program targeting the immune checkpoint VISTA, or V-set immunoglobulin domain suppressor of T cell activation.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs
- Company to focus on development of next-generation phage product candidates from ImmunoPhage platform and monoclonal antibody and nanobody programs - - Discontinuation of first-generation, single-antigen phage SNS-301 program upon analysis of clinical activity and antigen specific T-cell data - -
Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck
– Data continue to show that SNS-301 in combination with pembrolizumab is well tolerated – – One deep (71% tumor reduction) and durable (11 months) partial response and two longstanding (8 and 10 months) stable diseases observed in patients with no response to prior PD-1 blockade – – Data show
- ImmunoPhage™ platform programs and the VISTA program continue to advance - - New safety and efficacy data from ongoing Phase 1/2 combination study of SNS-301 in squamous cell carcinoma of the head and neck accepted for presentation at ASCO 2021 - - Patient dosing underway in second cohort of